Loading...
Current therapeutic approaches for Hodgkin lymphoma (HL) provide durable remissions and cure most patients. However, identifying the subset of patients at greatest risk for relapse or progression would permit early intervention with second-line therapies, including stem-cell transplantation.
Investigators at Stanford University retrospectively analyzed data from 81 HL patients who had been treated with the Stanford V regimen, which includes multiagent chemotherapy and involved-field radiation therapy (RT; 30 Gy to the pretreatment involved field and 36 Gy for nodal sites with original bulk >5 cm or for macroscopic splenic disease). Patients with nonbulky stage I or II disease and favorable risk received 8-week courses of chemotherapy, wherea…